Ethylene Glycol and Methanol Poisoning Treatment
|
|
|
- Milton McGee
- 10 years ago
- Views:
Transcription
1 Ethylene Glycol and Methanol Poisoning Treatment For many years, the only pharmacologic treatment for ethylene glycol or methanol toxicity was ethanol, given either orally or by continuous intravenous infusion. 1 Although effective for these indications, concern exists regarding ethanol s harmful side effect profile. The formulary at UK Hospital includes another antidote for ethylene glycol toxicity, fomepizole (Antizol ), which is also FDA approved for methanol poisonings. Fomepizole is a competitive inhibitor of alcohol dehydrogenase, with an affinity for the enzyme 8,000 times that of ethanol. 2 Alcohol dehydrogenase catalyzes the metabolism of ethylene glycol to glycoaldehyde, which is then oxidized to produce glycolic acid, glycoxylic acid, and oxalic acid. The metabolic acidosis and renal tubular damage associated with ethylene glycol ingestion are caused primarily by glycolic and oxalic acids respectively. 3, 4 Alcohol dehydrogenase also catalyzes the conversion of methanol to formaldehyde with subsequent oxidation to formic acid, resulting in the ocular damage and blindness associated with this metabolite. 1, 5 Fomepizole is effective in preventing the formation of toxic metabolites that are responsible for the complications of ethylene glycol and methanol poisoning. It appears to be most useful in patients who present soon after intoxication and who have not yet developed complications of ingestion. Largely due to the low incidence of methanol and ethylene glycol toxicities, comparison studies between ethanol and fomepizole are currently not available. The main disadvantage of fomepizole over ethanol is the acquisition cost. This difference in cost is magnified in patients with severe toxicity requiring hemodialysis, during which fomepizole needs to be dosed every four rather than every 12 hours. Unlike ethanol, fomepizole is not commonly associated with adverse effects such as CNS depression, hypoglycemia, hypothermia and agitation. Treatment with fomepizole may reduce costs if patients can be admitted to acute care areas rather than the intensive care unit while receiving the antidote. The dosing regimen of fomepizole does not require the frequent monitoring and subsequent adjustment of therapy that are necessary with ethanol treatment. Other laboratory monitoring, such as ethylene glycol and methanol serum concentrations, are still necessary. 1, 3 For these reasons, fomepizole s indication for use at UKH has been expanded to include both ethylene glycol and methanol toxicity. In addition, there are no longer UKH formulary restrictions for use according to the following guidelines. Deanna McMahon, Kyle Weant, Shane Winstead; 6/2009 Page 1 of 5
2 Guidelines for the Management of Ethylene Glycol (EG) and Methanol Poisoning If hemodialysis NOT indicated per renal consult, follow moderate intoxication treatment algorithm Deanna McMahon, Kyle Weant, Shane Winstead; 6/2009 Page 2 of 5
3 Fomepizole dosing in hemodialysis DOSE AT THE BEGINNING OF HEMODIALYSIS If < 6 hours since last fomepizole dose If 6 hours since last fomepizole dose Do not administer next scheduled dose. Administer next scheduled dose. DOSE DURING HEMODIALYSIS Administer dose every 4 hours. DOSE AT THE COMPLETION OF HEMODIALYSIS Time between last dose and end of hemodialysis Dose administered at end of hemodialysis session < 1 hour Do not administer dose at end of hemodialysis. 1 3 hours Administer 50% of next scheduled dose. > 3 hours Administer next scheduled dose. MAINTENANCE DOSE AFTER HEMODIALYSIS Give next scheduled dose 12 hours from last fomepizole dose if indicated. Deanna McMahon, Kyle Weant, Shane Winstead; 6/2009 Page 3 of 5
4 If fomepizole is indicated BUT there is history of hypersensitivity to fomepizole, ethanol should be used per the following guidelines (table 2). Ethanol should be titrated to a level of 100 mg/dl until ethylene glycol or methanol levels are below 20 mg/dl (see table 3 for ethanol contraindications). Table 2. Therapeutic Doses of Ethanol Based on Patient s Drinking History Absolute Ethanol Dose Volume of 10% IV Ethanol Solution Loading dose mg/kg ml/kg in D5W over 30 minutes Nondrinker Maintenance dose 66 mg/kg/hr 0.83 ml/kg/hr Maintenance dose during hemodialysis 169 mg/kg/hr 2.13 ml/kg/hr Chronic drinker Maintenance dose 154 mg/kg/hr 1.96 ml/kg/hr Maintenance dose during hemodialysis 257 mg/kg/hr 3.26 ml/kg/hr Table 3. Ethanol Contraindications Recovering alcoholic History of seizures Requiring close monitoring of CNS function Concurrent use of disulfiram (Antabuse ) or metronidazole (Flagyl ) Patient who is abstinent for religious reasons Deanna McMahon, Kyle Weant, Shane Winstead; 6/2009 Page 4 of 5
5 References: 1. Barceloux DG, Bond GR, Krenzelok EP, Cooper H, Vale JA. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. J Toxicol Clin Toxicol 2002;40: Antizol [package insert]. In. Palo Alto, CA: Jazz Pharmaceuticals, Inc; Barceloux DG, Krenzelok EP, Olson K, Watson W. American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol Poisoning. Ad Hoc Committee. J Toxicol Clin Toxicol 1999;37: Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for Toxic Alcohols Study Group. N Engl J Med 1999;340: Brent J, McMartin K, Phillips S, Aaron C, Kulig K. Fomepizole for the treatment of methanol poisoning. N Engl J Med 2001;344: Deanna McMahon, Kyle Weant, Shane Winstead; 6/2009 Page 5 of 5
Treatment of the alcohol intoxications: ethylene glycol, methanol and isopropanol Stuart Abramson and Ajay K. Singh
Treatment of the alcohol intoxications: ethylene glycol, methanol and isopropanol Stuart Abramson and Ajay K. Singh Intoxications with ethylene glycol, methanol, and isopropanol are among the most common
EMS Branch / Office of the Medical Director. Active Seziures (d) Yes Yes Yes Yes. Yes Yes No No. Agitation (f) No Yes Yes No.
M07 Medications 2015-07-15 All ages EMS Branch / Office of the Medical Director Benzodiazepines Primary Intermediate Advanced Critical INDICATIONS Diazepam (c) Lorazepam (c) Midazolam (c) Intranasal Midazolam
ENZYMES - EXTRA QUESTIONS
ENZYMES - EXTRA QUESTIONS 1. A chemical reaction has a G o = -60 kj/mol. If this were an enzyme-catalyzed reaction what can you predict about the kinetics? A. It will exhibit very rapid kinetics. B. It
1. According to recent US national estimates, which of the following substances is associated
1 Chapter 36. Substance-Related, Self-Assessment Questions 1. According to recent US national estimates, which of the following substances is associated with the highest incidence of new drug initiates
Update and Review of Medication Assisted Treatments
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
EFFIMET 1000 XR Metformin Hydrochloride extended release tablet
BRAND NAME: Effimet XR. THERAPEUTIC CATEGORY: Anti-Diabetic PHARMACOLOGIC CLASS: Biguanides EFFIMET 1000 XR Metformin Hydrochloride extended release tablet COMPOSITION AND PRESENTATION Composition Each
SPECIFICATION FOR THE LOCAL COMMISSIONED SERVICE FOR THE MANAGEMENT ALCOHOL MISUSE
SPECIFICATION FOR THE LOCAL COMMISSIONED SERVICE FOR THE MANAGEMENT OF ALCOHOL MISUSE Date: March 2015 1 1. Introduction Alcohol misuse is a major public health problem in Camden with high rates of hospital
The early symptoms of acute salicylism are the triad of gastrointestinal distress, tinnitus or altered hearing, and hyperventilation.
POISONING SALICYLATES (ASPIRIN) Management Guidelines Emergency Department Princess Margaret Hospital for Children Perth, Western Australia Last reviewed: January 2007 Page 1 of 5 Dr Gary Geelhoed Dr Frank
ALCOHOL WITHDRAWAL SYNDROME
ALCOHOL WITHDRAWAL SYNDROME INTRODUCTION Alcohol is the most commonly abused drug in the United States and when someone who chronically abuses alcohol does not drink, that person is at risk for developing
Acid Base Disorders. ACOI 2014 Board Review Case Studies
Acid Base Disorders ACOI 2014 Board Review Case Studies High Anion Gap Acidosis Case 1 40 yo gentleman presenting to ER with coma labs : ph 7.14/ pco2 15; Na 138/ K 6.4/ Cl 100/ HCO3 5; BS 100/ BUN 18/
Reducing Alcohol Health Harm
Employee Handbook of the Royal College of Physicians of Ireland RCPI Policy Group on Alcohol Reducing Alcohol Health Harm Supplementary Information: Biochemical Considerations with Alcohol Biochemical
Prior Authorization Guideline
Prior Authorization Guideline Guideline: PDP IBT Inj - Vivitrol Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Opiate Antagonist Client: 2007 PDP IBT Inj Approval Date: 2/20/2007
MEDICATIONS USED IN THE MANAGEMENT OF SUBSTANCE USE DISORDERS
MEDIATIONS USED IN THE MANAGEMENT OF SUBSTANE USE DISORDERS Opioid Agonist Therapy (OAT) for Opioid Dependence Methadone (Dolophine, Methadose) Specialty consultation advised. Titrate carefully, consider
VISTARIL (hydroxyzine pamoate) Capsules and Oral Suspension
VISTARIL (hydroxyzine pamoate) Capsules and Oral Suspension DESCRIPTION Hydroxyzine pamoate is designated chemically as 1-(p-chlorobenzhydryl) 4- [2-(2-hydroxyethoxy) ethyl] diethylenediamine salt of 1,1
Medication for the Treatment of Alcohol Use Disorder. Pocket Guide
Medication for the Treatment of Alcohol Use Disorder Pocket Guide Medications are underused in the treatment of alcohol use disorder. According to the National Survey on Drug Use and Health, of the estimated
How To Use Naltrexone Safely And Effectively
Naltrexone And Alcoholism Treatment Treatment Improvement Protocol (TIP) Series 28 Executive Summary and Recommendations Psychosocial treatments for alcoholism have been shown to increase abstinence rates
COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC)
London, 14 January 2010 EMA/HMPC/85114/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) REFLECTION PAPER ON ETHANOL CONTENT IN HERBAL MEDICINAL PRODUCTS 1 AND TRADITIONAL HERBAL MEDICINAL PRODUCTS USED
Alcohol Withdrawal. Introduction. Blood Alcohol Concentration. DSM-IV Criteria/Alcohol Abuse. Pharmacologic Effects of Alcohol
Pharmacologic Effects of Alcohol Alcohol Withdrawal Kristi Theobald, Pharm.D., BCPS Therapeutics III Fall 2003 Inhibits glutamate receptor function (NMDA receptor) Inhibits excitatory neurotransmission
Provision of Intravenous EDTA Chelation as a Complementary and Alternative Medicine
Provision of Intravenous EDTA Chelation as a Complementary and Alternative Medicine Guideline Updated: August 2010 Replaced: November 1998 To serve the public and guide the medical profession EDTA Chelation
Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).
Page 1 of 10 ANALYTE NAME AND STRUCTURE TERIFLUNOMIDE Teriflunomide TRADE NAME Aubagio CATEGORY Antimetabolite TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND sclerosis. The
Analytical Specifications RIVAROXABAN
Page 1 of 9 ANALYTE NAME AND STRUCTURE - RIVAROXABAN SYNONYMS Xarelto CATEGORY Anticoagulant TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND Xarelto (rivaroxaban) is an orally
Timothy Dougherty, MD, FAAEM, DCMT Medical Director, Cape Coral Emergency Physicians Cape Coral Hospital, Cape Coral FL
Timothy Dougherty, MD, FAAEM, DCMT Medical Director, Cape Coral Emergency Physicians Cape Coral Hospital, Cape Coral, FL Timothy Dougherty, MD, FAAEM, DCMT Medical Director, Cape Coral Emergency Physicians
Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial
Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial Barbara J. Mason, Ph.D. Professor, Committee on the Neurobiology of Addictive Disorders Director, Laboratory of Clinical Psychopharmacology
5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA [email protected] Dabigatran and Rivaroxaban:
How To Treat An Alcoholic Withdrawal
Alcohol Withdrawal Sorrento, Italy (September 19, 2007) Lewis R. Goldfrank, MD Professor and Chairman, Emergency Medicine New York University School of Medicine Director, Emergency Medicine Bellevue Hospital/NYU
Felimazole 5 mg Coated Tablet
.. CARTON TEXT - FRONT PANEL PRESCRIPTION ANIMAL REMEDY READ SAFETY DIRECTIONS BEFORE OPENING OR USING KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY RLP Approved Felimazole 5 mg Coated Tablet
Emergencies Related to ETHANOL (ETOH) Alcohol
University of Wisconsin Hospital and Clinics Emergency Education Center Emergencies Related to ETHANOL (ETOH) Alcohol Alcoholics are in all socio-economical levels of society ~ETOH is one of the most commonly
1. NAME OF THE MEDICINAL PRODUCT. Impavido 10 mg capsules Impavido 50 mg capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. 1 capsule contains:
1. NAME OF THE MEDICINAL PRODUCT Impavido 10 mg capsules Impavido 50 mg capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 capsule contains: Impavido 10 mg capsules 10 mg Miltefosine. Impavido 50 mg
Systematic Review of Treatment for Alcohol Dependence
Systematic Review of Treatment for Alcohol Dependence ALCOHOL ARCUATE NUCLEUS in Hypothalamus, pituitary Beta-endorphin Dynorphin Kappa receptor Nucleus Enkephalins accumbens Delta receptor (+) Mu receptor
DVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
Data Sheet. Paraldehyde
Data Sheet Paraldehyde Paraldehyde Injection Solution 100% Presentation Paraldehyde Injection BP is a sterile liquid containing paraldehyde BP with hydroquinone 100 micrograms/ml as an antioxidant. It
Master's Clinical Pharmacy (Thesis Track)
Master's Clinical Pharmacy (Thesis Track) I. GENERAL RULES CONDITIONS: Plan Number 3 \ 12 06 2010 T 1. This plan conforms to the valid regulations of the programs of graduate studies. 2. Areas of specialty
CARDIAC SURGERY INTRAVENOUS INSULIN PROTOCOL PHYSICIAN ORDERS INDICATIONS EXCLUSIONS. Insulin allergy
Page 1 of 5 INDICATIONS EXCLUSIONS 2 consecutive blood glucose measurements greater than 110 mg per dl AND NPO with a continuous caloric source AND Diagnosis of : Cardio-thoracic Surgery NOTE: This protocol
Nursing 113. Pharmacology Principles
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics
Clinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
Elements for a public summary. VI.2.1 Overview of disease epidemiology. VI.2.2 Summary of treatment benefits
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Pain is one of the most common reasons for a patient to seek medical attention. Moderate or severe intensity pain can be acute
Substance Use Learning Event Nov 3, 2015 Bill Bullock MD, CCFP
Substance Use Learning Event Nov 3, 2015 Bill Bullock MD, CCFP Medical assessment of patient with Alcohol Use Disorder Identification patients suitable for home detox Process for referral to inpatient
Review of Pharmacological Pain Management
Review of Pharmacological Pain Management CHAMP Activities are possible with generous support from The Atlantic Philanthropies and The John A. Hartford Foundation The WHO Pain Ladder The World Health Organization
PHARMACOLOGIC TREATMENT OF COMMON SUBSTANCE ABUSE DISORDERS LAUREN FISKE, MS4
PHARMACOLOGIC TREATMENT OF COMMON SUBSTANCE ABUSE DISORDERS LAUREN FISKE, MS4 ACUTE ALCOHOL INTOXICATION Naloxone for patients in coma and/or with respiratory depression (empiric treatment for opioid poisoning)
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
PARACETAMOL REXIDOL. 600 mg Tablet. Analgesic-Antipyretic. Paracetamol 600 mg
(Insert Text) UL Consumer Health PARACETAMOL REXIDOL 600 mg Tablet Analgesic-Antipyretic FORMULATION Each tablet contains: Paracetamol 600 mg PRODUCT DESCRIPTION Rexidol is a round, yellow, flat, bevel-edged
PARACETAMOL POISONING
Background Resuscitation Risk Assessment Supportive Care Decontamination Paracetamol Levels Nomogram Antidote N-acetylcysteine (NAC) Table NAC infusion guide Timing of Investigations Risk factors for Paracetamol
ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS
Antidote Use in the Critically Ill Poisoned Patient
ANALYTIC REVIEWS Antidote Use in the Critically Ill Poisoned Patient David P. Betten, MD* Rais B. Vohra, MD Matthew D. Cook, DO Michael J. Matteucci, MD Richard F. Clark, MD The proper use of antidotes
Alcohol-use disorders
Issue date: February 2011 Alcohol-use disorders Diagnosis, assessment and management of harmful drinking and alcohol dependence Alcohol dependence: NICE guideline FINAL DRAFT (February 2011) 1 NICE clinical
Proposal for deletion Codeine phosphate tablets for pain in children
Introduction Proposal for deletion Codeine phosphate tablets for pain in children Codeine is a phenanthrene opioid derivative. It is listed in the 2010 WHO Model List of Essential Medicines for Children
Prior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients
Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients Jennifer Kuhns, Pharm.D. Pharmacy Practice Resident Children s Hospital of Michigan **The speaker has no actual or potential
Medical Toxicology! Medicine! Infectious Disease! Acute and Critical Care Medicine 2
1 A medical subspecialty focused on the diagnosis, management and prevention of adverse health effects from medications, occupational & environmental toxins, and biological agents Medical Toxicology! SOLVENTS!
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES
PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement)
1 PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement) PHOSPHATE-SANDOZ PHOSPHATE-SANDOZ Tablets are a high dose phosphate supplement containing sodium phosphate monobasic. The CAS registry number
Treatment of Alcoholism
Treatment of Alcoholism Why is it important Prevents further to body by getting people off alcohol. Can prevent death. Helps keep health insurance down. Provides assistance so alcoholics don t t have to
Guidance for Industry Safety Testing of Drug Metabolites
Guidance for Industry Safety Testing of Drug Metabolites U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2008 Pharmacology
The author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 [email protected] This presentation will discuss unlabeled and investigational use of products The author
Designer Substances: Synthetic Cannabinoids and Cathinones - aka Spice/K2 and Bath Salts
Designer Substances: Synthetic Cannabinoids and Cathinones - aka Spice/K2 and Bath Salts Julie Knight, Pharm.D. Clinical Scientist Healthcare Services Aegis Sciences Corporation Objectives Discuss the
Diabetes Expert Witness on: Diabetic Hypoglycemia in Nursing Homes
Diabetes Expert Witness on: Diabetic Hypoglycemia in Nursing Homes Nursing home patients with diabetes treated with insulin and certain oral diabetes medications (i.e. sulfonylureas and glitinides) are
ACID-BASE DISORDER. Presenter: NURUL ATIQAH AWANG LAH Preceptor: PN. KHAIRUL BARIAH JOHAN
ACID-BASE DISORDER Presenter: NURUL ATIQAH AWANG LAH Preceptor: PN. KHAIRUL BARIAH JOHAN OBJECTIVES OF PRESENTATION 1. To refresh knowledge of acid-base disorders 2. To evaluate acid-base disorders using
Eight Guiding Principles for Effective Use of IVIG for Patients with Primary Immunodeficiency
Eight Guiding Principles for Effective Use of IVIG for Patients with Primary Immunodeficiency Primary immunodeficiency is caused by inherent defects of the immune system and results in recurrent, severe
Beaumont Hospital Department of Nephrology and Renal Nursing. Guideline for administering Ferinject
Beaumont Hospital Department of Nephrology and Renal Nursing Guideline Name: Guideline for administering Ferinject Guideline Number: 18 Guideline Version: a Developed By: Louise Kelly CNM 1 Renal Day Care
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK ACAMPROSATE CALCIUM (Campral EC) for alcohol abstinence ESCA: Adjunct in the treatment of chronic alcohol dependence (under
MEDICAL COVERAGE POLICY. SERVICE: Insulin Pump and Continuous Glucose Monitoring. PRIOR AUTHORIZATION: Required. POLICY:
Important note Even though this policy may indicate that a particular service or supply may be considered covered, this conclusion is not based upon the terms of your particular benefit plan. Each benefit
Original Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
Acute Poisoning Management Guidelines
EMERGENCY MEDICINE Acute Poisoning Management Guidelines Praveen Aggarwal*, Rohini Handa*, Jyoti Prakash Wali** With the availability of a vast number of chemicals and drugs, acute poisoning is a common
Maintenance of abstinence in alcohol dependence
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
Alcohol Abuse and Addiction Management Protocol
Alcohol Abuse and Addiction Management Protocol All Team Members: Patient Self-Management Education and Support Alcohol is the most commonly abused drug in the United States. About 18 million people in
SUMMARY OF PRODUCT CHARACTERISTICS. Paracetamol...10.00 mg for 1 ml of solution for infusion
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT PARACETAMOL MACOPHARMA 10 mg/ml, solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Paracetamol...10.00 mg for 1 ml of
Preconception Clinical Care for Women Medical Conditions
Preconception Clinical Care for Women All women of reproductive age are candidates for preconception care; however, preconception care must be tailored to meet the needs of the individual. Given that preconception
SUBSTANCE USE DISORDER SOCIAL DETOXIFICATION SERVICES [ASAM LEVEL III.2-D]
SUBSTANCE USE DISORDER SOCIAL DETOXIFICATION SERVICES [ASAM LEVEL III.2-D] I. Definitions: Detoxification is the process of interrupting the momentum of compulsive drug and/or alcohol use in an individual
Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
PRINCIPLES OF PHARMACOLOGY. MEDICAL ASSISTANT S ROLE History: Drug Legislation & Regulation. Education: indication, instructions, side effects
PRINCIPLES OF PHARMACOLOGY Medical Assistants At the heart of health care MEDICAL ASSISTANT S ROLE History: prescription over the counter (OTC) alcohol (ETOH), recreational, smoking, herbal remedies Education:
Drugs for Alcohol Dependence: Clinical Guidance and Three Way Agreement
Drugs for Alcohol Dependence: Clinical Guidance and Three Way Agreement for County Durham In partnership with the GP, the client, and the County Durham Drug and Alcohol Service December 2015 Version 1.0
MOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines
MOH CLINICL PRCTICE GUIELINES 2/2008 Prescribing of Benzodiazepines College of Family Physicians, Singapore cademy of Medicine, Singapore Executive summary of recommendations etails of recommendations
Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia
Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Insertion, removal or presence of a catheter in selected sites can place a patient who is antithrombotic agent at risk for a local bleeding
Alcohol-use disorders: alcohol dependence. Costing report. Implementing NICE guidance
Alcohol-use disorders: alcohol dependence Costing report Implementing NICE guidance February 2011 (February 2011) 1 of 37 NICE clinical guideline 115 This costing report accompanies the clinical guideline:
ABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
Ingestions, Intoxications, and the Critically Ill Child
Ingestions, Intoxications, and the Critically Ill Child Poisoning in Children 1 million cases of exposure to toxins in children younger than 6 years reported in the U.S. In 1993 estimated that another
MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Hepatitis C Agents that meet any of the following
Acamprosate calcium APOLLO 91991 46 950 950
Acamprosate calcium APOLLO 91991 46 950 950 Acamprosate calcium APOLLO 91991 46 950 950 Acamprosate calcium CAS Number : 77337-73-6 Molecular Weight : 400.48 g/mol Molecular Formula : 2C5H10NO4S.Ca Systematic
Copyright 2010 Pearson Education, Inc. Chapter Fourteen 1
An alcohol has an OH bonded to an alkyl group; a phenol has an OH bonded directly to an aromatic ring; and an ether has an O bonded to two organic groups. Chapter Fourteen 1 Ethyl alcohol, dimethyl ether,
Calcium Folinate Ebewe Data Sheet
NAME OF THE MEDICINE Calcium folinate injection Composition Active: Calcium folinate (equivalent to 10 mg folinic acid per ml) Inactive: Sodium chloride (7.7mg/mL), qs Water for Injections. Preservative
The Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool
The Pharmacological Management of Cancer Pain in Adults Clinical Audit Tool 2015 This clinical audit tool accompanies the Pharmacological Management of Cancer Pain in Adults NCEC National Clinical Guideline
